CRISPR/Cas9 knockout of G9a suppresses HCC cell proliferation and migration in vitro and inhibits HCC tumorigenicity in vivo, suggesting that targeted application of CRISPR/Cas9 can halt HCC development both in vitro and in vivo [70]. Here, EHMT2 is linked to hepatocellular carcinoma.